411 Results for "

Conformational

" in MedChemExpress (MCE) Product Catalog:
Products (411)

411 Results for "Conformational" in MCE Product Catalog:

127
127 Publications Verification
Cat. No.: HY-15463
CAS No.: 152459-95-5
Purity:  99.95%
Synonyms: STI571; CGP-57148B
Research Areas:  

Cancer

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively . Imatinib also is an inhibitor of SARS-CoV and MERS-CoV .
loading...
    loading...
63
63 Cited Publications
Cat. No.: HY-130149
CAS No.: 2326521-71-3
Purity:  99.81%
Synonyms: MRTX849
Target:  

Ras

Research Areas:  

Cancer

Adagrasib (MRTX849) is a potent, orally-available, and mutation-selective covalent inhibitor of KRAS G12C with potential antineoplastic activity. Adagrasib covalently binds to KRAS G12C at the cysteine at residue 12, locks the protein in its inactive GDP-bound conformation, and inhibits KRAS-dependent signal transduction .
loading...
    loading...
29
29 Cited Publications
Cat. No.: HY-16926
CAS No.: 442633-00-3
Target:  

Arp2/3 Complex HIV

Research Areas:  

Infection Cancer

CK-666 is a cell-permeable actin-related protein Arp2/3 complex inhibitor (IC50=12 μM). CK-666 binds to Arp2/3 complex, stabilizes the inactive state of the complex, blocking movement of the Arp2 and Arp3 subunits into the activated filament-like (short pitch) conformation .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-13991
CAS No.: 285986-88-1
Purity:  99.88%
Target:  

Ras Apoptosis

Research Areas:  

Cancer

CCG-1423 is an inhibitor of Rho/MRTF/SRF pathway. CCG-1423 shows activities in several cancer cells. CCG-1423 is a promising lead compound for the development of novel pharmacologic tools, and it can be used for the research of cancer and diabetes .
loading...
    loading...
14
14 Cited Publications
Cat. No.: HY-101561
CAS No.: 1703793-34-3
Purity:  99.75%
Synonyms: BLU-285
Target:  

c-Kit PDGFR

Research Areas:  

Cancer

Avapritinib (BLU-285) is a highly potent, selective, and orally active KIT and PDGFRA activation loop mutant kinases inhibitor with IC50s of 0.27 and 0.24 nM for KIT D816V and PDGFRA D842V, respectively. Avapritinib (BLU-285) binds the active conformation of the kinase and shows antitumor activity. Avapritinib (BLU-285) attenuates the transport function of both ABCB1 and ABCG2 .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-134539
CAS No.: 2304621-31-4
Purity:  98.13%
IMT1 is a first-in-class specific and noncompetitive human mitochondrial RNA polymerase (POLRMT) inhibitor. IMT1 causes a conformational change of POLRMT, which blocks substrate binding and transcription in a dose-dependent way in vitro. IMT1 reduces deoxynucleoside triphosphate levels and citric acid cycle intermediates, resulting in a marked depletion of cellular amino acid levels. IMT1 has the potential for mitochondrial transcription disorders related diseases .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740
CAS No.: 114681-65-1
Target:  

Integrin Apoptosis Caspase

Research Areas:  

Inflammation/Immunology

RGD peptide (GRGDNP) is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
9
9 Cited Publications
Cat. No.: HY-P1740A
Target:  

Integrin Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

RGD peptide (GRGDNP) TFA is an inhibitor of integrin-ligand interactions. RGD peptide (GRGDNP) TFA competitively inhibits α5β1 binding with extracellular matrice (ECM). RGD peptide (GRGDNP) TFA promotes apoptosis through activation of conformation changes that enhance pro-caspase-3 activation and autoprocessing. RGD peptide (GRGDNP) TFA plays an important role in cell adhesion, migration, growth, and differentiation .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-18669
CAS No.: 100872-83-1
Target:  

HSP

Research Areas:  

Cancer

ML346 is an activator of Hsp70 expression and HSF-1 activity, with an EC50 of 4.6 μM for Hsp70. ML346 restores protein folding in conformational disease models, without significant cytotoxicity or lack of specificity. ML346 induces specific increases in genes and protein effectors of the heat shock response (HSR), including chaperones such as Hsp70, Hsp40, and Hsp27 .
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112306
CAS No.: 1442472-39-0
Purity:  98.21%
Synonyms: DCC-2618
Research Areas:  

Cancer

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-112096
CAS No.: 1914078-41-3
Purity:  99.17%
Synonyms: NXP900
Target:  

Src

Research Areas:  

Cancer

eCF506 (NXP900) is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-109176
CAS No.: 1953133-47-5
Purity:  99.52%
Synonyms: GDC-9545; RG6171
Target:  

Estrogen Receptor/ERR

Research Areas:  

Cancer

Giredestrant (GDC-9545), a non-steroidal estrogen receptor (ER) ligand, is an orally active and selective ER antagonist. Giredestrant potently competes with Estradiol for binding and induces a conformational change within the ER ligand binding domain. Giredestrant has anti-tumor activity .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-113298
CAS No.: 498-23-7
Purity:  98.73%
Synonyms: Methylmaleic acid
Citraconic acid (Methylmaleic acid) is an orally active inhibitor targeting the NLRP3 inflammasome and Keap1-Nrf2 pathway. Citraconic acid reduces reactive oxygen species (ROS) generation by inhibiting succinate dehydrogenase (SDH) activity. Citraconic acid also modifies the conformation of Keap1 protein, relieves its inhibition of Nrf2, promotes antioxidant gene expression, and inhibits NLRP3 activation and the release of pro-inflammatory factors such as IL-1β and IL-18. Citraconic acid has anti-inflammatory and antioxidant activities, can reduce oxidative stress and cell pyroptosis, improve tissue damage, and can be used for the research of inflammation-related diseases such as acute renal ischemia-reperfusion injury. Citraconic acid is an isomer of Itaconic acid (HY-Y052) .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-19896
CAS No.: 1039455-84-9
Target:  

MDM-2/p53 Apoptosis

Research Areas:  

Cancer

COTI-2, an anti-cancer agent with low toxicity, is an orally available third generation activator of p53 mutant forms. COTI-2 acts both by reactivating mutant p53 and inhibiting the PI3K/AKT/mTOR pathway. COTI-2 induces apoptosis in multiple human tumor cell lines. COTI-2 exhibits antitumor activity in HNSCC through p53-dependent and -independent mechanisms. COTI-2 converts mutant p53 to wild-type conformation .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P99129

Research Areas:  

Inflammation/Immunology

Anti-Mouse CD8a Antibody (53-6.7) is an anti-mouse CD8a IgG2a antibody inhibitor derived from host Rat. Anti-Mouse CD8a Antibody (53-6.7) binds to CD8αβ stabilizes a conformation with a higher affinity for interaction with MHC class I. Anti-Mouse CD8a Antibody (53-6.7) induces the phosphorylation and activation of TCR proximal signaling pathway components Lck and ZAP70 in polyclonal memory T cells. Anti-Mouse CD8a Antibody (53-6.7) depletes CD8+ T cells and neutralizes cytokine in mice .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-B0178A
CAS No.: 50-01-1
Synonyms: Guanidinium chloride; Aminoformamidine hydrochloride
Guanidine hydrochloride (Guanidinium chloride) is a strong protein denaturant. Guanidine hydrochloride causes proteins to assume a random coil conformation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1454
CAS No.: 2247635-23-8
Synonyms: Ac-LPSDDLEFWCHVMY-NH2
Target:  

Wnt

Research Areas:  

Cancer

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 impairs the function of FZD7 in Wnt–β-catenin signalling and stem cell function in intestinal organoids .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1454A
Synonyms: Ac-LPSDDLEFWCHVMY-NH2 TFA
Target:  

Wnt

Research Areas:  

Cancer

Fz7-21 (Ac-LPSDDLEFWCHVMY-NH2) TFA is a potent peptide antagonist of FZD7 receptors , selectively binds to FZD7 CRD subclass and alters the conformation of the CRD and the architecture of its lipid-binding groove. The EC50 values are 58 and 34 nM for human and mouse FZD7 CRD, respectively. Fz7-21 TFA impairs the function of FZD7 in Wnt-β-catenin signalling and stem cell function in intestinal organoids .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13299
CAS No.: 1001917-37-8
Purity:  98.34%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-13299A
CAS No.: 1283000-43-0
Purity:  99.86%
Target:  

c-Met/HGFR

Research Areas:  

Cancer

MK-8033 hydrochloride is an orally active ATP competitive c-Met/Ron dual inhibitor (IC50s: 1 nM (c-Met),7 nM (Ron)), with preferential binding to the activated kinase conformation. MK-8033 hydrochloride can be used in the research of cancers, such as breast and bladder cancers, non-small cell lung cancers (NSCLCs) .
loading...
    loading...